Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.79 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.63 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138342 | 0.88 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL29635879 | 0.88 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL29389124 | 0.88 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL14423736 | 0.86 | TRPV1 (0.80) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL4267012 | 0.84 | TRPV1 (0.63) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL13930734 | 0.83 | TRPV1 (0.69) | TRPV1TRPA1KCNH2TRPM8 | |
| SCHEMBL10308206 | 0.82 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL19417039 | 0.81 | TRPV1 (0.58) | TRPV1CNR2 | |
| SCHEMBL4550113 | 0.79 | TRPV1 (0.66) | TRPV1 | |
| SCHEMBL1269620 | 0.78 | TRPV1 (1.00) | TRPV1TRPA1KCNH2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176443-A1 | Capsaicin receptor ligands | NEUROGEN CORPORATION | 2004-09-09 | — | — | US | claimed |
| US-6723730-B2 | DIARYL PIPERAZINES AND RELATED COMPOUNDS USEFUL IN THE TREATMENT OF A CHRONIC AND ACUTE PAIN CONDITIONS, ITCH AND URINARY INCONTINENCE. | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| EP-1301484-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020132853-A1 | Capsaicin receptor ligands | NEUROGEN CORPORATION | 2002-09-19 | — | — | US | claimed |
| WO-2002008221-A2 | CAPSAICIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-31 | — | — | WO | claimed |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2010-09-16 | — | — | US | disclosed |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| WO-2008057300-A9 | TRPVI ANTAGONISTS AND USES THEREOF | REDPOINT BIO CORP (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080153845-A1 | TRPV1 ANTAGONISTS AND USES THEREOF | REDPOINT BIO CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153845-A1 | TRPV1 ANTAGONISTS AND USES THEREOF | REDPOINT BIO CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008057300-A2 | TRPVI ANTAGONISTS AND USES THEREOF | REDPOINT BIO CORPORATION (US) | 2008-05-15 | — | — | WO | disclosed |
| US-7256193-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-08-14 | — | — | US | disclosed |
| US-7256193-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-08-14 | — | — | US | disclosed |
| EP-1581225-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-6723730-B2 | DIARYL PIPERAZINES AND RELATED COMPOUNDS USEFUL IN THE TREATMENT OF A CHRONIC AND ACUTE PAIN CONDITIONS, ITCH AND URINARY INCONTINENCE. | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176443-A1 | Capsaicin receptor ligands | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885TRPA1 4/4885KCNH2 403/4885 |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | TRPV1, TRPA1, TRPV5 | TRPV1 1/4885TRPA1 2/4885KCNH2 641/4885 |
| US-20080153845-A1 | TRPV1 ANTAGONISTS AND USES THEREOF | TRPV1, TRPA1, TRPV5 | TRPV1 1/4885TRPA1 2/4885KCNH2 323/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | TRPV1 36/4885TRPA1 101/4885KCNH2 442/4885 |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | CNR1, CNR2, AVPR1A | TRPV1 9/4885TRPA1 68/4885KCNH2 262/4885 |
| US-20020132853-A1 | Capsaicin receptor ligands | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885TRPA1 4/4885KCNH2 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.